Premium
Predominant factors associated with bone loss in liver transplant patients – after prolonged post‐transplantation period
Author(s) -
Segal Elena,
Baruch Yakov,
Kramsky Rimma,
Raz Batia,
Tamir Ada,
IshShalom Sophia
Publication year - 2003
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1034/j.1399-0012.2003.02065.x
Subject(s) - medicine , femoral neck , prednisone , liver transplantation , transplantation , tacrolimus , osteoporosis , vitamin d and neurology , bone mineral , glucocorticoid , gastroenterology , bone density , surgery , endocrinology , urology
Introduction: Osteoporosis is a major cause of morbidity in liver transplant recipients and is associated with multiple factors. Objectives: To evaluate bone mineral density (BMD), bone turnover and calcium‐regulating hormones in 29 patients (17 men, 12 women) 2–12 yrs following liver transplantation for non‐alcoholic liver diseases. Results: Fifteen patients (52%) were on immunosuppressive treatment with tacrolimus and 14 (48%) with cyclosporine. Eleven patients (38%) were currently on prednisone, 18 patients (62%) had stopped glucocorticoid treatment 6 months to 11 yrs prior to the study. Nineteen patients (65.5%) had decreased BMD according to WHO criteria, 17 (58.2%) at the femoral neck, 13 (44.8%) at the lumbar spine. Nineteen patients (65.5%) had a subnormal (<15 ng/mL) serum level of 25 (OH) D3. These patients had significantly lower BMD at the femoral neck (p = 0.02). Femoral neck BMD negatively correlated with serum parathyroid hormone level (p = 0.06, r = −0.35), length of the post‐transplantation period (p = 0.025, r = −0.416) and duration of glucocorticoid treatment (p = 0.029, r = −0.406), regardless of its cumulative dose. Symptomatic fractures were less frequent in tacrolimus treated patients than in cyclosporine users (p = 0.03). Conclusions: Decreased BMD is frequent following liver transplantation and is affected by vitamin D deficiency, cyclosporine use, and the duration of glucocorticoid therapy, but not by its cumulative dose. Achievement and maintenance of optimal vitamin D status and shortening of glucocorticoid treatment period may have a favorable effect on bone preservation.